Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001258347
Ethics application status
Approved
Date submitted
22/08/2017
Date registered
30/08/2017
Date last updated
15/01/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
A Single-Center, Open-Label Pharmacokinetic (PK) Study to Assess the PK Profile of Nicotine Delivered by the Chrono Quit Smoking Solution (CQSS2)
Scientific title
A Single-Center, Open-Label Pharmacokinetic (PK) Study in male smokers to Assess the PK Profile of Nicotine Delivered by the Chrono Quit Smoking Solution (CQSS2)
Secondary ID [1] 292703 0
PK2017-008
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
cigarette addiction
 304459 0
Condition category
Condition code
Mental Health 303798 303798 0 0
Addiction

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The Chrono Quit Smoking Solution (CQSS2) is a Nicotine Replacement Therapy System. The dosing period consists of one day with approximately 21 mg of nicotine delivered transdermally using the CQSS2. Doses of 5.4% nicotine formulation are delivered transdermally via the CQSS2 worn either on the upper arm or mid-thigh at programmed intervals of T0, T0.5, T1, T7, T7.5, T13 hours. Participants are required to stay in the clinic for the one day treatment and required to wear the CQSS2 for approximately 24 hours for a full PK parameters evaluation. The CQSS2 treatment will be administered by the health care provider. A strap (i.e., Comfort Band), will be the primary method used to attach the CQSS2 to the body.
Intervention code [1] 298943 0
Treatment: Drugs
Intervention code [2] 298964 0
Treatment: Devices
Comparator / control treatment
Participants will be randomly allocated to wear the CQSS2 on either the upper arm or the mid-thigh.
Control group
Active

Outcomes
Primary outcome [1] 303158 0
PK concentration profile of nicotine delivered by the Chrono Quit Smoking Solution (CQSS2) system
Timepoint [1] 303158 0
PK analysis over 30 hours:
blood samples will be collected approximately 15 mins prior to the first dose, every 20 minutes for the first 2 hours, at Hour 2.5, hourly from Hour 3 through Hour 16, then every 2 hours thereafter through Hour 30.
Secondary outcome [1] 338057 0
Safety of the Chrono Quit Smoking Solution (CQSS2) system
Vital signs will be monitored periodically throughout the active period of dosing for possible adverse events of: Bradycardia (resting pulse rate <40 beats per minute [bpm]); Tachycardia (resting pulse rate >120 bpm); Blood pressure <90 or >165 mmHg systolic; Blood pressure <45 or >105 mmHg diastolic.
Timepoint [1] 338057 0
Adverse events will be collected from the time of the application of the CQSS2 through the Follow-up visit (within 14 days of discharge).
Secondary outcome [2] 338221 0
Tolerability of the Chrono Quit Smoking Solution (CQSS2) system
Skin irritation at the CQSS2 application site will be assessed on an 8-point Skin Irritation Assessment scale
Timepoint [2] 338221 0
Skin irritation at the CQSS2 application site will be assessed on an 8-point Skin Irritation Assessment scale (0 to 7) up to 30 minutes prior to placement of the system, immediately after removal of the system at the 30 hour time point, and at the Follow-up visit. Any score more than or equal to 3 will be reported as an AE and documented with photographic evidence. All application site AEs will be followed until the event is resolved, returns to baseline, or the Follow-up visit (within 14 days of discharge), whichever occurs first.

Eligibility
Key inclusion criteria
Smokers consuming on average more than or equal to 10 cigarettes per day for at least the past 6 months, confirmed by self report
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
infections
opiate use
males who consume more than 4 alcoholic beverages per day for the past month
tattoos that could interfere with skin assessments

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Pharmacokinetics
Statistical methods / analysis
Pharmacokinetic endpoints will be evaluated and summarized descriptively.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
18/10/2017
Actual
18/10/2017
Date of last participant enrolment
Anticipated
18/10/2017
Actual
26/10/2017
Date of last data collection
Anticipated
20/10/2017
Actual
14/11/2017
Sample size
Target
10
Accrual to date
Final
10
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 8843 0
Nucleus Network - Melbourne
Recruitment postcode(s) [1] 16978 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 297342 0
Commercial sector/Industry
Name [1] 297342 0
Chrono Therapeutics Australia PTY LTD
Country [1] 297342 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Chrono Therapeutics Australia PTY LTD
Address
C/-MPR Group PTY LTD
Floor 19, HWT Tower
40 City Road
Southbank
Victoria 3004
Country
Australia
Secondary sponsor category [1] 296319 0
Commercial sector/Industry
Name [1] 296319 0
Nucleus Network Limited (Trading as Centre for Clinical Studies)
Address [1] 296319 0
5th Floor Burnet Tower, 89 Commercial Road, Melbourne
Victoria 3004
Country [1] 296319 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298442 0
The Alfred Ethics Committee
Ethics committee address [1] 298442 0
Ethics committee country [1] 298442 0
Australia
Date submitted for ethics approval [1] 298442 0
30/08/2017
Approval date [1] 298442 0
27/09/2017
Ethics approval number [1] 298442 0
442/17

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 77106 0
Dr Jason Lickliter
Address 77106 0
Nucleus Network 5th Floor Burnet Tower 89 Commercial Road Melbourne
Victoria 3004
Country 77106 0
Australia
Phone 77106 0
+61 3 9076 8960
Fax 77106 0
+61 (3) 9076 8900
Email 77106 0
[email protected]
Contact person for public queries
Name 77107 0
Cameron Johnson
Address 77107 0
Nucleus Network 5th Floor Burnet Tower 89 Commercial Road Melbourne
Victoria 3004
Country 77107 0
Australia
Phone 77107 0
+61 3 9076 8906
Fax 77107 0
+61 (3) 9076 8900
Email 77107 0
[email protected]
Contact person for scientific queries
Name 77108 0
Patricia Oto
Address 77108 0
Chrono Therapeutics Australia PTY LTD
3953 Point Eden Way,
Hayward, CA 94545
Country 77108 0
United States of America
Phone 77108 0
+1-925-286-6992
Fax 77108 0
None
Email 77108 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.